Australia's most trusted
source of pharma news
Monday, 01 June 2026
Posted 1 June 2026 AM
Accelegan has secured the TGA’s approval for Haruropi, a systemic transdermal Parkinson’s disease treatment patch.
Developed by Hisamitsu Pharmaceutical, the patch contains ropinirole, the same active ingredient used in Arrotex’s oral treatments for restless legs syndrome, such as Appese, Repreve, and Ropinirole ARW.

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.